ATE534623T1 - 2-alkyliden-18,19-dinor-vitamin-d-verbindungen - Google Patents

2-alkyliden-18,19-dinor-vitamin-d-verbindungen

Info

Publication number: ATE534623T1
Authority: AT; Austria
Prior art keywords: compounds; activity; alkylidene; diseases; treatment
Prior art date: 2004-04-09

Application number

AT05722702T

Other languages

English (en)

Inventor

Hector Deluca

Rafal Barycki

Pawel Grzywacz

Lori Plum

Rafal Sicinski

Original Assignee

Wisconsin Alumni Res Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-09

Filing date

2005-02-04

Publication date

2011-12-15

2005-02-04 Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found

2011-12-15 Application granted granted Critical

2011-12-15 Publication of ATE534623T1 publication Critical patent/ATE534623T1/de

Links

150000001875 compounds Chemical class 0.000 title abstract 6
229940088594 vitamin Drugs 0.000 title 1
229930003231 vitamin Natural products 0.000 title 1
235000013343 vitamin Nutrition 0.000 title 1
239000011782 vitamin Substances 0.000 title 1
210000000988 bone and bone Anatomy 0.000 abstract 3
230000000694 effects Effects 0.000 abstract 3
238000011282 treatment Methods 0.000 abstract 2
208000023275 Autoimmune disease Diseases 0.000 abstract 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
208000001132 Osteoporosis Diseases 0.000 abstract 1
201000004681 Psoriasis Diseases 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
229910052791 calcium Inorganic materials 0.000 abstract 1
239000011575 calcium Substances 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
230000004069 differentiation Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000011540 hip replacement Methods 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
230000000968 intestinal effect Effects 0.000 abstract 1
238000013150 knee replacement Methods 0.000 abstract 1
206010025135 lupus erythematosus Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
210000001616 monocyte Anatomy 0.000 abstract 1
201000006417 multiple sclerosis Diseases 0.000 abstract 1
230000011164 ossification Effects 0.000 abstract 1
230000035755 proliferation Effects 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
230000027425 release of sequestered calcium ion into cytosol Effects 0.000 abstract 1
208000017520 skin disease Diseases 0.000 abstract 1
238000001356 surgical procedure Methods 0.000 abstract 1
230000002194 synthesizing effect Effects 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1
239000011710 vitamin D Substances 0.000 abstract 1
229940046008 vitamin d Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Transplantation (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT05722702T 2004-04-09 2005-02-04 2-alkyliden-18,19-dinor-vitamin-d-verbindungen ATE534623T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10/821,828 US7713951B2 (en)	2004-04-09	2004-04-09	2-alkylidene-18,19-dinor-vitamin D compounds
PCT/US2005/003378 WO2005102995A1 (en)	2004-04-09	2005-02-04	2-alkylidene-18,19-dinor-vitamin d compounds

Publications (1)

Publication Number	Publication Date
ATE534623T1 true ATE534623T1 (de)	2011-12-15

Family

ID=34960524

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05722702T ATE534623T1 (de)	2004-04-09	2005-02-04	2-alkyliden-18,19-dinor-vitamin-d-verbindungen

Country Status (9)

Country	Link
US (2)	US7713951B2 (de)
EP (1)	EP1735277B1 (de)
JP (1)	JP4988551B2 (de)
AT (1)	ATE534623T1 (de)
AU (1)	AU2005235957B2 (de)
CA (1)	CA2562535C (de)
MX (1)	MXPA06011499A (de)
NZ (1)	NZ550234A (de)
WO (1)	WO2005102995A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7834050B2 (en)	2006-03-29	2010-11-16	Duke University	Small molecule insulin mimetics absent quinones
JP2009533483A (ja) *	2006-04-06	2009-09-17	ウイスコンシンアラムニリサーチファンデーション	２−メチレン−１α，２５−ジヒドロキシ−１８，１９，２１−トリノルビタミンＤ３およびその使用
AU2007298651A1 (en) *	2006-04-06	2008-03-27	Wisconsin Alumni Research Foundation	2-methylene-1 alpha-hydroxy-18,19,21-trinorvitamin D3 analogs and uses thereof
WO2010082837A1 (en) *	2009-01-16	2010-07-22	Jan Anne Lyftogt	Medicament for the treatment of pain and inflammation
ES2437921T3 (es) *	2009-10-21	2014-01-15	Wisconsin Alumni Research Foundation	Método para prevenir la diabetes tipo 1
US8664206B2 (en)	2010-03-23	2014-03-04	Wisconsin Alumni Research Foundation	Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
AU2011232633B2 (en) *	2010-03-23	2014-05-29	Wisconsin Alumni Research Foundation	(20S)-2-methylene-19-nor-22-dimethyl-1alpha,25- dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22- dimethyl-1alpha,25-hydroxyvitamin D3
JP5931845B2 (ja) *	2010-03-23	2016-06-08	ウイスコンシンアラムニリサーチファンデーション	２−メチレン−１９−ノル−２２−メチル−１α，２５−ジヒドロキシビタミンＤ３のジアステレオマー
JP5930467B2 (ja) *	2012-12-14	2016-06-08	花王株式会社	ニトリル化合物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0078704B1 (de)	1981-11-02	1987-04-29	Research Institute For Medicine And Chemistry Inc.	Zwischenprodukte in der Synthese von Vitamin D Derivaten
US4666634A (en)	1984-12-05	1987-05-19	Chugai Seiyaku Kabushiki Kaisha	vitamin D3 derivatives having a substituent at 2-position
GB8904154D0 (en)	1989-02-23	1989-04-05	Leo Pharm Prod Ltd	Chemical compounds
US5246925A (en)	1989-03-09	1993-09-21	Wisconsin Alumni Research Foundation	19-nor-vitamin D compounds for use in treating hyperparathyroidism
NZ232734A (en)	1989-03-09	1991-11-26	Wisconsin Alumni Res Found	19-nor vitamin d derivatives and pharmaceutical compositions
CA1333616C (en)	1989-03-09	1994-12-20	Hector F. Deluca	19-nor-vitamin d compounds
AU649057B2 (en)	1990-08-24	1994-05-12	Wisconsin Alumni Research Foundation	Methods and compositions containing vitamin D compounds for improvement of skin conditions
DE69130497T2 (de)	1990-09-07	1999-04-22	Wisconsin Alumni Research Foundation, Madison, Wis.	Neue Verwendung von 1-Alpha-hydroxylierten-19-nor-vitamin-D-Verbindungen zur Behandlung von Psoriasis
AU650751B2 (en)	1991-05-28	1994-06-30	Wisconsin Alumni Research Foundation	Novel synthesis of 19-nor vitamin D compounds
US5086191A (en)	1991-05-28	1992-02-04	Wisconsin Alumni Research Foundation	Intermediates for the synthesis of 19-nor vitamin D compounds
DE69400495T2 (de)	1993-04-05	1997-04-30	Wisconsin Alumni Res Found	19-Nor-vitamin-D3-Verbindung mit einem Substituent an die 2. Stelle
PT972762E (pt) *	1993-07-09	2004-02-27	Theramex	Novos analogos estruturais da vitamina d
WO1996001811A1 (en)	1994-07-11	1996-01-25	The Johns-Hopkins University	2-substituted 1,25-dihydroxyvitamin d3 derivatives
EP0793649B1 (de)	1994-11-21	1999-02-03	Wisconsin Alumni Research Foundation	18,19-dinor-vitamin-d-derivate
US5661140A (en) *	1994-11-21	1997-08-26	Wisconsin Alumni Research Foundation	18-nor-vitamin D compounds
US5877168A (en)	1995-02-10	1999-03-02	Chugai Seiyaku Kabushiki Kaisha	Vitamin D derivative with substituent at the 2β-position
CA2175881A1 (en)	1995-05-09	1996-11-10	Andrzej Kutner	Vitamin d compounds and methods of preparing these compounds
US5945410A (en)	1997-03-17	1999-08-31	Wisconsin Alumni Research Foundation	2-alkyl-19-nor-vitamin D compounds
US6392071B1 (en) *	1997-03-17	2002-05-21	Wisconsin Alumni: Research Foundation	26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US5843928A (en)	1997-03-17	1998-12-01	Wisconsin Alumni Research Foundation	2-alkylidene-19-nor-vitamin D compounds
US6114317A (en) *	1998-05-21	2000-09-05	Wisconsin Alumni Research Foundation	Method of locking 1α-OH of vitamin D compounds in axial orientation
US5972917A (en) *	1998-05-29	1999-10-26	Bone Care Int Inc	1 α-hydroxy-25-ene-vitamin D, analogs and uses thereof
TW396427B (en) *	1998-12-16	2000-07-01	United Microelectronics Corp	Method for fabricating double gates in semiconductor
US6806262B2 (en) *	2000-05-31	2004-10-19	Wisconsin Alumni Research Foundation	2-ethyl and 2-ethylidene-19-nor-vitamin D compounds
WO2002005823A2 (en) *	2000-07-14	2002-01-24	Wisconsin Alumni Research Foundation	USE OF 2-METHYLENE-19-NOR-20(S)-1α,25-DIHYDROXYVITAMIN D3 TO INCREASE BONE STRENGTH
WO2002020021A1 (en) *	2000-09-08	2002-03-14	Wisconsin Alumni Research Foundation	1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications
BR0307896A (pt) *	2002-03-29	2004-12-07	Wisconsin Alumni Res Found	Método de produção de 1(alfa)-hidroxi-2-metileno-19-nor-homopregnacalcif erol
EP1559708A4 (de) *	2002-10-10	2006-07-19	Wisconsin Alumni Res Found	2,2-disubstituiertes 1a,25-dihydroxy-19-norvitamin-d-derivat
BRPI0409194A (pt) *	2003-04-10	2006-04-11	Wisconsin Alumni Res Found	compostos, composição farmacêutica e método de tratamento de doença metabólica do osso, da psorìase, da leucemia, cáncer do cólon, cáncer da mama, cáncer da pele ou cáncer da próstata, de doença auto-imune, de doença inflamatória do intestino e de aumento da resistência do osso
US6894037B2 (en) *	2003-07-03	2005-05-17	Wisconsin Alumni Research Foundation	2-methylene-19-nor-20(S)-25-methyl-1α-hydroxycalciferol and its uses
AU2004266706B2 (en) *	2003-08-20	2009-07-30	Wisconsin Alumni Research Foundation	2-methylene-19-nor-vitamin D2 compounds
US7214670B2 (en) *	2003-09-24	2007-05-08	Wisconsin Alumni Research Foundation	Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 to increase the life expectancy of human beings
US7053075B2 (en) *	2003-11-25	2006-05-30	Deluca Hector F	Methods for reducing body fat using vitamin D compounds
CA2544502A1 (en) *	2003-11-25	2005-06-09	Wisconsin Alumni Research Foundation	Vitamin d analogs for obesity prevention and treatment
ATE467614T1 (de) *	2004-11-22	2010-05-15	Wisconsin Alumni Res Found	2-methylen-19,26,27-trinor-(20s)-1-alpha- hydroxyvitamin d3 and dessen verwendungen
US7238681B2 (en) *	2004-11-22	2007-07-03	Wisconsin Alumni Research Foundation	2-Methylene-18,19-dinor-1α-hydroxy-homopregnacalciferol and its uses
NZ561076A (en) *	2005-02-11	2010-01-29	Wisconsin Alumni Res Found	2-methylene-19-nor-(20S-24EPI)-1alpha,25-dihydroxyvitamin-D2
CA2605727A1 (en) *	2005-05-03	2006-11-09	Wisconsin Alumni Research Foundation	19,26,27-trinor-1.alpha.,25-dihydroxyvitamin d3 compounds

2004
- 2004-04-09 US US10/821,828 patent/US7713951B2/en not_active Expired - Fee Related
2005
- 2005-02-04 JP JP2007507308A patent/JP4988551B2/ja not_active Expired - Fee Related
- 2005-02-04 WO PCT/US2005/003378 patent/WO2005102995A1/en not_active Ceased
- 2005-02-04 EP EP05722702A patent/EP1735277B1/de not_active Expired - Lifetime
- 2005-02-04 MX MXPA06011499A patent/MXPA06011499A/es active IP Right Grant
- 2005-02-04 AT AT05722702T patent/ATE534623T1/de active
- 2005-02-04 CA CA2562535A patent/CA2562535C/en not_active Expired - Fee Related
- 2005-02-04 NZ NZ550234A patent/NZ550234A/en not_active IP Right Cessation
- 2005-02-04 AU AU2005235957A patent/AU2005235957B2/en not_active Ceased
2010
- 2010-02-19 US US12/709,181 patent/US20100179344A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2005102995A1 (en)	2005-11-03
JP2007532540A (ja)	2007-11-15
AU2005235957A1 (en)	2005-11-03
NZ550234A (en)	2010-07-30
EP1735277A1 (de)	2006-12-27
AU2005235957B2 (en)	2011-08-04
US7713951B2 (en)	2010-05-11
CA2562535A1 (en)	2005-11-03
EP1735277B1 (de)	2011-11-23
MXPA06011499A (es)	2007-01-16
JP4988551B2 (ja)	2012-08-01
US20050227950A1 (en)	2005-10-13
US20100179344A1 (en)	2010-07-15
CA2562535C (en)	2012-07-10

Publication	Publication Date	Title
MXPA03000405A (es)	2003-06-06	Uso de 2 alfa-metil-19-nor-20(s)-1alfa,25-dihdroxivitamina d3 para incrementar la resistencia de los huesos.
MXPA03000406A (es)	2003-06-06	Uso de 2-metilen-19-nor-20(s)-1 alfa,25-dihidroxivitamina d3 para incrementar la resistencia de los huesos.
ATE556999T1 (de)	2012-05-15	2-propyliden-19-nor-vitamin d verbindungen
ATE415164T1 (de)	2008-12-15	(20s)-1alpha-hydroxy-2alpha-methyl und 2beta- methyl-19-nor vitamin d3 und ihre verwendung
ATE537834T1 (de)	2012-01-15	2-methylen-19-nor-vitamin d2-verbindungen
Kunz et al.	2014	Effects of immobilization and remobilization on the ankle joint in Wistar rats
De La Mata	2013	Platelet rich plasma. A new treatment tool for the rheumatologist?
BR9808010B1 (pt)	2013-11-26	Compostos de 2-alquil-19-nor-vitamina d e composição farmacêutica compreendendo os mesmos
MXPA02009590A (es)	2004-03-26	Compuestos de 2-alquiliden-19-norvitamina d y sus usos terapeuticos.
PE20050255A1 (es)	2005-06-02	Nuevas cianotiazolidas y procedimiento para su preparacion como medicamentos
ATE534623T1 (de)	2011-12-15	2-alkyliden-18,19-dinor-vitamin-d-verbindungen
CA2403232A1 (en)	2001-10-11	26,27-homologated-20-epi-2-alkyl-19-nor-vitamin d compounds
MX2007006263A (es)	2007-07-10	Analogos 2a-metil y 2??-metil de 19,26,27-trinor-(20s)-1a- hidroxivitamina d3 y sus usos.
MX2007006261A (es)	2007-07-10	Analogos de 17,20(z)-deshidro vitamina d y sus usos.
Liu et al.	2024	Mesenchymal stem cells and their exosomes mitigate osteoarthritis by restoring the balance between proinflammatory Teffs and Tregs
ATE350043T1 (de)	2007-01-15	2-methylen-19-nor-20(s)-25-methyl-1alpha- hydroxycalciferol und seine verwendungen
WO2010006162A3 (en)	2010-05-20	2-methylene-(20e)-20(22)-dehydro-19-nor-vitamin d analogs
Ferreira et al.	2011	Functional outcome of bicondylar tibial plateau fractures treated with the Ilizarov circular external fixator
Fatahi et al.	2021	The effect of aerobic exercise combined with bone marrow mesenchymal stem cells on inflammatory biomarkers levels of the brain in a model of osteoarthritic rat
NL2039507B1 (en)	2025-08-25	Composition containing fish bone powder and plant extract for effective improvement in bone joint health
Huang et al.	2023	Bone Marrow Mesenchymal Stem Cells Inhibits Inflammation and Promotes Chondrocyte Activity in Knee Arthritis Rats
Chen et al.	2020	Growth Arrest Specific Gene 6 Affects Osteogenesis of Bone Marrow Mesenchymal Stem Cells in Inflammatory Environment via MAPK/AKT Signaling Pathway
Iyer	2016	The Adult Hip and Its Disorders
Xu et al.	2010	Variation of articular cartilages under abnormal stress
Katsarov et al.	2011	Epiphyseal Complex and Growth Arrest